Seminars in Oncology
Volume 30, Issue 2 , Pages 116-120 , April 2003

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

References 

  1. Waldenstrom J. To treat or not to treat, this is the real question. Leuk Res. 1991;15:407–408
  2. Dimopoulos MA, Panayiotis P, Moulapoulos LA, et al.  Waldenström's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol. 2000;18:214–226
  3. Garcia-Sanz R, Montoto S, Torrequebrada A, et al.  Waldenström's macroglobulinaemia: Presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115:575–582
  4. Facon T, Brouillard M, Duhamer A, et al.  Prognostic factors in Waldenström's macroglobulinemia: A report of 167 cases. J Clin Oncol. 1993;11:1158–1553
  5. Dimopoulos MA, Alexanian R. Waldenström's macroglobulinaemia. Blood. 1994;83:1452–1459
  6. Gobbi PG, Bettini R, Montecucco C, et al.  Study of prognosis in Waldenstrom's macroglobulinemia: A proposal for a simple binary classification with clinical and investigational utility. Blood. 1994;83:2939–2945
  7. Merlini G, Baldini L, Broglia C, et al.  Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:211–215
  8. Morel P, Monconduit M, Jacomy D, et al.  Prognostic factors in Waldenström macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96:852–858
  9. Dhodapkar MV, Jacobson JL, Gertz MA, et al.  Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: Results of United States intergroup trial (South West Oncology Group S9003). Blood. 2001;98:41–48
  10. Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK, et al.  Waldenström's macroglobulinemia: Clinical course and prognostic factors in 60 patients. Am Hematol. 2001;80:722–727
  11. Andriko JA, Aguilera NS, Chu WS, et al.  Waldenström's macroglobulinemia: A clinicopathologic study of 22 cases. Cancer. 1997;80:1926–1935
  12. Mansoor A, Meideiros LJ, Weber DM, et al.  Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with polymorphous subtype and an aggressive clinical course. Am J Pathol. 2001;116:543–549
  13. Owen RG, Barrans SL, Richards SJ, et al.  Waldenström's macroglobulinaemia. Development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001;116:420–428
  14. Mackenzie MR, Fudenberg HH. Macroglobulinemia: An analysis of forty patients. Blood. 1972;39:874–889
  15. Brouet JC, Clauvel JP, Seligmann M. Evolution et pronostic de la maladie de Waldenström: Etude de 150 observations. Act Hematol. 1975;9:38–47
  16. Alexanian R, Weber D, Delasalle K, et al.  Asymptomatic Waldenström's disease. Semin Oncol. 2003;30:206–210
  17. Cesana C, Miqueleiz S, Bernuzzi P, et al.  Smoldering Waldenstrom's macroglobulinemia: Factors predicting evolution to symptomatic disease. Semin Oncol. 2003;30:231–235

☆ Address reprint requests to Waldenstrom's Macroglobulinemia Program, Dana Farber Cancer Institute, Harvard Medical School, LG100, 44 Binney St, Boston, MA 02115.

☆☆ 0093-7754/03/3002-0003$30.00/0

PII: S0093-7754(03)70060-8

doi: 10.1053/sonc.2003.50038

Seminars in Oncology
Volume 30, Issue 2 , Pages 116-120 , April 2003

Article Tools